At today’s ISPOR Real-World Evidence Summit 2025 , Puneet Kaushik presented new insights into the economic burden of Japanese Encephalitis(JE) across Asia-Pacific.
🔍 Despite vaccines and treatments, JE continues to strain health systems through:
• High inpatient and ICU demands
• Significant productivity losses—up to 860 workdays per case
• Wide cost variability: from $106 to $1,644 per case across countries
This systematic review drew from real-world data in China, Bangladesh, Indonesia, the Philippines and multi-country studies.
But key data gaps remain—particularly from Japan.
More regional research is needed to inform vaccination strategies and public health investments.
What’s your take on improving RWE coverage in underrepresented APAC settings?
